What is the recommended approach for formal diagnosis and treatment of suspected scalp psoriasis?

Diagnosis and Treatment of Scalp Psoriasis

For suspected scalp psoriasis, diagnosis is primarily clinical based on characteristic erythematous plaques with silvery-white scales, and first-line treatment is combination calcipotriene plus betamethasone dipropionate gel or foam for 4-12 weeks. 1

Formal Diagnosis

Clinical Diagnosis

• Diagnosis is established through clinical examination identifying well-demarcated, erythematous plaques with silvery-white scales on the scalp 1, 2
• Examine the entire body for additional psoriatic lesions on elbows, knees, presacral region, nails, and other characteristic sites to support the diagnosis 1, 3
• Trichoscopy (dermoscopy of the scalp) can aid diagnosis by revealing specific patterns: twisted red loop vessels, red dots and globules, and characteristic scale patterns 2

When to Biopsy

• Skin biopsy is reserved for atypical presentations or when differentiation from seborrheic dermatitis, atopic eczema, or contact dermatitis is uncertain 2, 3

Key Differential Diagnoses to Consider

• Seborrheic dermatitis (greasy yellow scales vs. silvery-white scales) 2, 3
• Atopic eczema (less well-demarcated, different distribution) 3
• Contact dermatitis (allergic or irritant, requires detailed exposure history) 3

Treatment Algorithm

First-Line Therapy (Mild to Moderate Disease)

Combination calcipotriene 0.005% plus betamethasone dipropionate 0.064% gel or foam is the recommended first-line treatment for 4-12 weeks 1

• This combination achieved 69-74% clear or almost clear status in clinical trials, significantly superior to either agent alone 1
• Apply once daily for initial treatment 1
• No serious adverse events including striae or HPA axis suppression were observed over 52 weeks of use 1

Alternative First-Line Options

If combination product unavailable, use separate topical corticosteroids (class 1-7) for minimum 4 weeks as initial therapy 1

• Class 1 ultrahigh-potency corticosteroids (clobetasol, halobetasol) for thick, resistant plaques 1
• Class 2-5 moderate-to-high potency for less severe involvement 1

Maintenance Therapy

Two evidence-based maintenance regimens after initial clearance: 1

1. Vitamin D analogue twice daily on weekdays + high-potency corticosteroid twice daily on weekends 1
2. High-potency corticosteroid in morning + vitamin D analogue in evening 1

Second-Line Therapy (Inadequate Response to Topicals)

For patients failing topical therapy after 4-12 weeks, consider:

• Intralesional triamcinolone acetonide up to 20 mg/mL every 3-4 weeks for localized resistant lesions 1, 4
• Phototherapy or excimer laser for resistant cases 4

Systemic Therapy (Moderate to Severe Disease)

When scalp psoriasis is part of moderate-to-severe body psoriasis (>10% BSA) or causes significant quality of life impairment despite topical therapy: 1, 4

Biologics with proven scalp efficacy (in order of evidence strength):

• IL-17 inhibitors: ixekizumab, bimekizumab, secukinumab, brodalumab 5, 6
• IL-23 inhibitors: guselkumab, icotrokinra, tildrakizumab 5, 6
• TNF-alpha inhibitors: etanercept (particularly if psoriatic arthritis present) 1

Small molecule options:

• Apremilast, deucravacitinib (modest efficacy for scalp) 4, 5, 6

Conventional systemics:

• Methotrexate, cyclosporine, acitretin 7

Critical Pitfalls to Avoid

• Never combine salicylic acid with calcipotriene - the acidic pH inactivates calcipotriene and reduces effectiveness 1
• Apply vitamin D analogues after phototherapy, not before, to avoid inactivation by UVA and blocking of UVB 1
• Avoid abrupt withdrawal of topical corticosteroids - taper gradually after clinical improvement to prevent rebound 1
• Monitor for corticosteroid adverse effects when using class 1 agents, though risk is lower on scalp than face or intertriginous areas 1

Monitoring and Treatment Goals

• Reassess every 4 months during first year to evaluate response and adjust therapy 2
• Treatment success defined as clear (0) or almost clear (1) on Physician's Global Assessment 1, 5
• If inadequate response after 12 weeks of appropriate topical therapy, escalate to systemic treatment 4, 7